Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Debt Ratio (2016 - 2025)

Historic Debt Ratio for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 0.61.

  • ImmunityBio's Debt Ratio fell 1884.71% to 0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61, marking a year-over-year decrease of 1884.71%. This contributed to the annual value of 0.74 for FY2024, which is 14106.81% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Debt Ratio is 0.61, which was down 1884.71% from 0.76 recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Debt Ratio ranged from a high of 1.5 in Q1 2021 and a low of 0.31 during Q4 2023
  • Moreover, its 5-year median value for Debt Ratio was 0.76 (2025), whereas its average is 0.87.
  • Per our database at Business Quant, ImmunityBio's Debt Ratio skyrocketed by 2230531.88% in 2021 and then tumbled by 4721.17% in 2022.
  • Over the past 5 years, ImmunityBio's Debt Ratio (Quarter) stood at 0.65 in 2021, then skyrocketed by 61.89% to 1.06 in 2022, then tumbled by 70.87% to 0.31 in 2023, then surged by 141.07% to 0.74 in 2024, then decreased by 17.98% to 0.61 in 2025.
  • Its Debt Ratio stands at 0.61 for Q3 2025, versus 0.76 for Q2 2025 and 0.98 for Q1 2025.